A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Q4 2024 Management View CEO Helen Torley highlighted record-breaking performance in 2024, with total revenue surpassing $1 billion, a 22% year-over-year growth. Key milestones included approvals for ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon. My name ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.